Biopharma company Aptinyx Inc. says its phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia did not achieve statistically significant separation from placebo on the study’s primary endpoint. “We are very disappointed that, despite the evidence of activity observed in a prior biomarker study in fibromyalgia patients, in this follow-up phase … Continue reading Aptinyx fibromyalgia drug misses endpoint